ANI Pharmaceuticals Inc (ANIP)
Receivables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 614,376 | 486,816 | 316,385 | 216,136 | 208,475 |
Receivables | US$ in thousands | — | — | — | — | — |
Receivables turnover | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $614,376K ÷ $—K
= —
The receivables turnover ratio for ANI Pharmaceuticals Inc is not available for the years 2020, 2021, 2022, 2023, and 2024. This ratio provides insights into how efficiently the company is collecting payments from its customers. Without this information, it is difficult to assess the company's effectiveness in managing its accounts receivable and converting them into cash. It would be beneficial to obtain this data in order to better understand ANI Pharmaceuticals Inc's financial performance and liquidity position.
Peer comparison
Dec 31, 2024
Company name
Symbol
Receivables turnover
ANI Pharmaceuticals Inc
ANIP
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
4.05
Amphastar P
AMPH
5.37
Arcus Biosciences Inc
RCUS
51.60
Biomarin Pharmaceutical Inc
BMRN
4.31
Bristol-Myers Squibb Company
BMY
4.49
Catalyst Pharmaceuticals Inc
CPRX
—
Collegium Pharmaceutical Inc
COLL
—